CD19 and hematologic disorder: CAR-T in vivo persistence is a key factor in determining CAR-T function,47 which relies on an appropriate strength of tonic signaling.14 Two types of CARs, CD19 and CD22, currently being used to target hematologic malignancies, exhibit weak tonic signals.